- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04803175
Sacubitril/Valsartan Versus Valsartan in Heart Failure With Improved Ejection Fraction (PROSPER-HF)
Prospective Comparison of Sacubitril/Valsartan Versus Valsartan on the Outcome of Heart Failure With Improved Ejection Fraction: a Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
1. Background and study purpose Heart failure (HF) is caused by structural or functional abnormality of the myocardium or elevated intracardiac pressures, resulting in symptoms and signs of low cardiac output or congestion, such as dyspnea, peripheral edema, elevated jugular venous pressures, pulmonary congestion, and fatigue. HF with reduced left ventricular ejection fraction (HFrEF) is defined as an LVEF <40% by the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines. Recent guidelines recommend the use of angiotensin-converting enzyme inhibitors (ACEI)/angiotensin II receptor blocker (ARB)/angiotensin receptor neprilysin inhibitor (ARNI), beta blockers (BB), aldosterone antagonists (AA), and sodium-glucose co-transporter-2 inhibitors (SGLT2i) in HFrEF patients. ACEI/ARB/ARNI, collectively known as renin-angiotensin-system (RAS) blockers, are considered the most important drug class in the treatment for HFrEF and recently, ARNI is increasingly preferred as the first-choice drug. Unlike for initial treatment of HFrEF, continued treatment for patients who experience recovery of LVEF is not as well established. In these patients, called heart failure with improved ejection fraction (HFiEF), it is not clear whether continued treatment with sacubitril/valsartan or valsartan is beneficial in terms of relapse of heart failure or worsening of LVEF. Therefore, the investigators aim to determine whether the treatment with sacubitril/valsartan versus valsartan differs in clinical outcomes after 1 year in HFiEF patients by observing the change in serum N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and clinical relapse of HF.
2. Registry factors
- Source data verification will be done by comparing the data to electronic medical records and paper and electronic case report forms.
- Data dictionary with detailed description of each variables are given.
- Sample size assessment was calculated by comparing mean NT-proBNP levels at baseline and after 12 months in the two groups by two-sample t-test (two-sided, effect size=0.6, type I error=0.05, type II error=0.8, allocation ratio=1). With a drop-out rate of 10%, 50 patients in each group are needed. As the change of NT-proBNP in HFiEF with sacubitril/valsartan or valsartan has rarely been reported, estimation from the TRED-HF study (Lancet. 2019 Jan 5; 393(10166):61) was used as reference for effect size. This reference was a small study of 25 patients in each group. Therefore, the effect size used for calculation was modified to 0.6 rather than 0.8 by intuition of the investigators.
- Plan for missing data: To avoid unavailable data, clinical visits will be monitored and calls will be made for missed appointments. Uninterpretable or out-of-range results will be discussed by participating investigators through regular meetings.
- Statistical analysis Based on intention-to-treat analysis, the primary outcome (NT-proBNP changes) will be log-transformed and compared by paired t-tests. Baseline characteristics will be presented according to initial drug assignment and compared with the Mann-Whitney test for continuous variables or Fisher's exact test for categorical variables. Data are presented as median and IQR or as n (%). Occurrence of the secondary endpoint will be graphically displayed per group with Kaplan-Meier survival plots and compared with the log-rank test. Cox proportional hazards models will be used to investigate predictors of worsening NT-proBNP levels or occurrence of clinical adverse events in patients of each group. A p value less than 0.05 will be considered significant.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Jinoh Choi, MD, PhD
- Phone Number: 82234103417
- Email: choijean5@gmail.com
Study Contact Backup
- Name: Yoonjee Park, MD
- Phone Number: 821026729748
- Email: yoonjeedrpark@gmail.com
Study Locations
-
-
-
Seoul, Korea, Republic of, 06351
- Recruiting
- Samsung Medical Center
-
Contact:
- Jinoh Choi, MD, PhD
- Phone Number: 82234103417
- Email: choijean5@gmail.com
-
Contact:
- Yoonjee Park, MD
- Phone Number: 821026729748
- Email: yoonjeedrpark@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
- Consecutive participant sampling was done for all eligible patients.
- Patients visiting a specialized heart failure clinic at one of the top tertiary level hospitals in Seoul, Korea. Patients have a nationwide distribution geographically, and show a wide range of clinical presentations.
Description
Inclusion Criteria: (AND)
- Patient with a history of HF with reduced EF (HFrEF; LVEF <40 percent) and received treatment with sacubitril/valsartan for at least 3 months, after which showing improvement of LVEF to >40 percent and symptoms of NYHA functional class I or II
- serum NT-proBNP levels < 400 pg/dL for sinus rhythm and < 600pg/dL for atrial fibrillation
- Patients on stable doses of diuretics for 1 week
Exclusion Criteria: (OR)
- History of hospitalization for heart failure within 30 days before enrollment
- History of acute coronary syndrome (acute myocardial infarction or unstable angina), percutaneous coronary artery intervention or cardiac surgery within 30 days before enrollment
- History of cardiac resynchronization therapy within 90 days before screening
- Planned percutaneous or surgical coronary artery revascularization, or major cardiac surgery (coronary artery bypass, valvuloplasty, mechanical cardiac support or heart transplantation) within 90 days after enrollment
- Contraindicated or has history of hypersensitivity to RAS blockers including ACEI or ARB
- Use of inotropes
- Survival estimate < 3months
- Otherwise deemed as inappropriate by the attending physician
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Sacubitril/valsartan
Patients undergoing continued treatment with sacubitril/valsartan after improvement of LVEF >40% with > 3 months of sacubitril/valsartan treatment.
Dose and titration schedule will be individualized by discretion of the attending physician.
|
Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months.
The investigator does not assign specific interventions to the study participants.
Other Names:
|
Valsartan
Patients undergoing continued treatment with valsartan after improvement of LVEF >40% with > 3 months of sacubitril/valsartan treatment.
Dose and titration schedule will be individualized by discretion of the attending physician.
|
Participants will receive individualized dosage and titration as part of routine medical care, and a the effect will be studied for at least 12 months.
The investigator does not assign specific interventions to the study participants.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in NT-proBNP concentration
Time Frame: Baseline, 6 months, 12 months
|
pg/ml
|
Baseline, 6 months, 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Heart failure relapse
Time Frame: 6 months and 12 months
|
One or more of the following:
|
6 months and 12 months
|
Hospitalization for heart failure (HHF)
Time Frame: 6 months and 12 months
|
Hospitalization for acute decompensated heart failure
|
6 months and 12 months
|
Death caused by heart failure
Time Frame: 6 months and 12 months
|
Heart failure being either the immediate or contributing cause of death.
|
6 months and 12 months
|
Mortality
Time Frame: 6 months and 12 months
|
All-cause mortality
|
6 months and 12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
left ventricular (LV) ejection fraction (LVEF, percent)
Time Frame: 6 months (optional, personalized) and 12 months
|
measurement based on echocardiography with the following priority
|
6 months (optional, personalized) and 12 months
|
LV end-systolic dimension (LVESD, mm)
Time Frame: 6 months (optional, personalized) and 12 months
|
measurement based on echocardiography with the following priority
|
6 months (optional, personalized) and 12 months
|
LV end-diastolic dimension (LVEDD, mm)
Time Frame: 6 months (optional, personalized) and 12 months
|
measurement based on echocardiography with the following priority
|
6 months (optional, personalized) and 12 months
|
LV mass index (LVMI; g/m^2)
Time Frame: 6 months (optional, personalized) and 12 months
|
Calculated by the following measurements based on echocardiography. Equation: LVMI = LV mass / BSA
IVSd: Interventricular septum dimension (mm)* PWd: LV Posterior wall dimension (mm)* BSA: body surface area (kg/m^2) calculated from weight (kg) and height (m) at the timing of echocardiography (BSA = weight/ (height)^2 * LVEDD, IVSd, PWd are measured with the following priority
|
6 months (optional, personalized) and 12 months
|
Left atrial volume index (LAVI, ml/m^2)
Time Frame: 6 months (optional, personalized) and 12 months
|
LAVI = LA volume (ml) /BSA (m^2)
|
6 months (optional, personalized) and 12 months
|
E/E' ratio
Time Frame: 6 months (optional, personalized) and 12 months
|
measurements based on echocardiography E: by pulsed wave Doppler of mitral inflow velocity E': by tissue Doppler of early diastolic mitral annulus velocity
|
6 months (optional, personalized) and 12 months
|
Right ventricular systolic pressure (RVSP, mmHg)
Time Frame: 6 months (optional, personalized) and 12 months
|
Right ventricular systolic pressure (RVSP) estimated by Tricuspid valve Regurgitation jet maximum velocity (TR Vmax) base on continuous wave Doppler echocardiographic measurements. Modified Bernoulli equation: RVSP = 4V^2 + RA pressure(*) * RA pressure (mmHg) is estimated by the following:
|
6 months (optional, personalized) and 12 months
|
LV 4-dimensional strain (percent)
Time Frame: 6 months (optional, personalized) and 12 months
|
Using a Vivid E9, E90, E95 ultrasound system (GE Healthcare, Chicago, IL, USA) with a 2.5-3.6 MHz 4-dimensional Volume transducer, a 4D full-volume scan is obtained from the apical position during an end-expiratory apnea. From a twelve-slice display mode, the examiner ensures that the whole LV structure be included in the 4D full-volume image. The frame rate was required to be over 40 percent of the heart rate (HR). The global strain values, including LV GLS, GRS, GCS, and GAS, were automatically calculated by the software. Specific techniques are described in (Eur J Echocardiogr. 2011 Jan;12(1):26-32. doi: 10.1093/ejechocard/jeq095. Epub 2010 Aug 24.) * GLS = global longitudinal strain; GRS = global radial strain; GCS = global circumferential strain; GAS = global area strain; |
6 months (optional, personalized) and 12 months
|
Change in hemoglobin (g/dL)
Time Frame: Baseline, 6 months and 12 months
|
Changes in laboratory values between time periods
|
Baseline, 6 months and 12 months
|
Change in albumin (g/dL)
Time Frame: Baseline, 6 months and 12 months
|
Changes in laboratory values between time periods
|
Baseline, 6 months and 12 months
|
Change in total bilirubin (mg/dL)
Time Frame: Baseline, 6 months and 12 months
|
Changes in laboratory values between time periods
|
Baseline, 6 months and 12 months
|
Change in fasting blood glucose (mg/dL)
Time Frame: Baseline, 6 months and 12 months
|
Changes in laboratory values between time periods
|
Baseline, 6 months and 12 months
|
Change in blood urea nitrogen (mg/dL)
Time Frame: Baseline, 6 months and 12 months
|
Changes in laboratory values between time periods
|
Baseline, 6 months and 12 months
|
Change in creatinine (mg/dL)
Time Frame: Baseline, 6 months and 12 months
|
Changes in laboratory values between time periods
|
Baseline, 6 months and 12 months
|
Change in estimated GFR (ml/min/1.73m^2)
Time Frame: Baseline, 6 months and 12 months
|
Changes in laboratory values between time periods Calculated by CKD-EPI equation CKD-EPI eGFR(mL/min/1.73m^2) = A × (Scr/B)^C × 0.993^(age) , where A, B, and C are the following: Female Scr ≤0.7; A = 144, B = 0.7, C = -0.329 Scr ≤0.9; A = 141, B = 0.9, C = -0.411 Male Scr >0.7; A = 144, B = 0.7, C = -1.209 Scr >0.9; A = 141, B = 0.9, C = -1.209 |
Baseline, 6 months and 12 months
|
Change in sodium (mmol/L)
Time Frame: Baseline, 6 months and 12 months
|
Changes in laboratory values between time periods
|
Baseline, 6 months and 12 months
|
Change in potassium (mmol/L)
Time Frame: Baseline, 6 months and 12 months
|
Changes in laboratory values between time periods
|
Baseline, 6 months and 12 months
|
Change in hemoglobin A1c (percent)
Time Frame: Baseline, 6 months and 12 months
|
Changes in laboratory values between time periods
|
Baseline, 6 months and 12 months
|
Reason for discontinuation of study drug
Time Frame: 6 months and 12 months
|
Choose one answer from the following:
[*] Shock as defined in (N Engl J Med 2013; 369:1726-1734). [**] Renal dysfunction defined as:
|
6 months and 12 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, Jackson R, Rahneva T, Wage R, Smith G, Venneri L, Tayal U, Auger D, Midwinter W, Whiffin N, Rajani R, Dungu JN, Pantazis A, Cook SA, Ware JS, Baksi AJ, Pennell DJ, Rosen SD, Cowie MR, Cleland JGF, Prasad SK. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019 Jan 5;393(10166):61-73. doi: 10.1016/S0140-6736(18)32484-X. Epub 2018 Nov 11.
- Januzzi JL Jr, Prescott MF, Butler J, Felker GM, Maisel AS, McCague K, Camacho A, Pina IL, Rocha RA, Shah AM, Williamson KM, Solomon SD; PROVE-HF Investigators. Association of Change in N-Terminal Pro-B-Type Natriuretic Peptide Following Initiation of Sacubitril-Valsartan Treatment With Cardiac Structure and Function in Patients With Heart Failure With Reduced Ejection Fraction. JAMA. 2019 Sep 17;322(11):1085-1095. doi: 10.1001/jama.2019.12821.
- Wilcox JE, Fang JC, Margulies KB, Mann DL. Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel. J Am Coll Cardiol. 2020 Aug 11;76(6):719-734. doi: 10.1016/j.jacc.2020.05.075.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-08-082
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure, Systolic
-
Central Hospital, Nancy, FranceUnknown
-
Zensun Sci. & Tech. Co., Ltd.Active, not recruitingChronic Systolic Heart FailureChina
-
Zensun Sci. & Tech. Co., Ltd.TerminatedChronic Systolic Heart FailureChina
-
Jiangsu HengRui Medicine Co., Ltd.UnknownChronic Systolic Heart FailureChina
-
Hospital Moinhos de VentoTakedaUnknownHeart Failure, Systolic | Systolic Heart Failure | Cardiac FailureBrazil
-
Merck KGaA, Darmstadt, GermanyMerck Ltd.Completed
-
University of NebraskaEli Lilly and Company; Daiichi Sankyo, Inc.Completed
-
Abbott Medical DevicesCompletedSystolic Heart FailureAustralia, Hong Kong, Japan
-
University of CincinnatiCompletedSystolic Heart FailureUnited States
-
Novartis PharmaceuticalsCompletedHeart FailureRussian Federation, Germany, Poland
Clinical Trials on Sacubitril-Valsartan
-
Qingdao Central HospitalNot yet recruitingMyocardial Infarction | HypertensionChina
-
Viatris Inc.Not yet recruiting
-
Novartis PharmaceuticalsCompleted
-
Damanhour UniversityTanta UniversityCompleted
-
Novartis PharmaceuticalsCompleted
-
University of Alabama at BirminghamNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular Diseases | Hypertension | Obesity | Nocturnal Blood Pressure | Natriuretic Peptides | Renin-Angiotensin-Aldosterone SystemUnited States
-
Bio-innova Co., LtdNot yet recruiting
-
Novartis PharmaceuticalsCompletedHeart Failure With Preserved Ejection Fraction (HFpEF)United States, Canada
-
Viatris Inc.Not yet recruitingBioequivalence StudyThailand
-
University Hospital, ToulouseTerminated